We are live on ! Find out more

Pacira BioSciences

PCRX

Market cap $1.01B

25.36 USD

+0.20

0.79%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

25.36

0.00

0%

1 day

0.79%

5 days

-3.87%

1 month

4.02%

3 months

8.56%

6 months

11.08%

Year to date

3.68%

1 year

-6.18%

5 years

-54.34%

10 years

-37.1%

About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Employees: 829

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.8%

Neutral 66.7%

Negative 5.6%

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences is evolving from a single-product specialty pharma into a self-funded musculoskeletal pain platform with expanding pipeline optionality. EXPAREL's separate reimbursement, particularly via the NOPAIN Act and UnitedHealthcare, shifts economics and broadens institutional access, supporting recurring protocol-based utilization. The iovera° divestiture strengthens PCRX's balance sheet, funds higher-value pharmaceutical programs, and preserves upside through milestone payments.

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Zacks Investment Research

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences NASDAQ: PCRX reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet.

Pacira BioSciences Q2 Earnings Call Highlights

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.74 per share a year ago.

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Pacira BioSciences Reports Second Quarter 2026 Financial Results

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.

Pacira BioSciences Reports Second Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™